Page 2 - முன்னணி உலகளாவிய வழங்குநர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Resideo Appoints Kareem Yusuf to Board of Directors
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Rocket Lab and Spire Global join SPAC space race to challenge Elon Musk s SpaceX
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Rocket Lab and Spire Global join SPAC space race to challenge Elon Musk s SpaceX
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Submission is eligible for priority review and accelerated approvalWAYNE, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational freeze dried plasma (FDP) candidate. The investigational FDP is a lyophilized (freeze dried) unit of human plasma being developed under a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA). The investigational FDP is subject to the amendments made to section 564 of the Federal Food, Drug, and Cosmetic Act under H.R 4374 [Public Law No: 115-92]. This law allows for authorization of additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war.1 “This is an exciting milestone for Teleflex. We look fo
Resideo Technologies, Inc. (NYSE: REZI), a leading global provider of home comfort and security solutions, today announced that the company has completed the refinancing of its senior secured term loan A and term loan B with the net proceeds of a new 7-year, $950 million senior secured term loan B maturing in 2028. The interest rate on the new term loan B is LIBOR + 225 basis points. The company also entered into a new 5-year, $500 million revolving credit facility. The credit facility matures in 2026 and carries an interest rate that is initially LIBOR + 225 basis points on borrowings but is subject to reduction based upon the company's leverage ratio.